generated-image

The benefit of catheter-based reperfusion for acute myocardial infarction (MI) is limited by a 5 % to 15 % incidence of in-hospital major ischemic events, usually caused by infarct artery reocclusion, and a 20 % to 40 % need for repeat percutaneous or surgical revascularization. Platelets play a key role…

As compared with thrombolytic therapy, primary percutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death, reinfarction, and stroke, but recurrent ischemia, restenosis, and reocclusion of the infarct-related artery remain problematic. When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further…

Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of the coronary vessel during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal-antibody Fab fragment (c7E3) directed against the platelet glycoprotein IIb/IIIa receptor, in patients undergoing…

Low-dose alteplase with standard-dose abciximab enhances reperfusion 90 minutes after acute myocardial infarction (MI). We combined standard-dose abciximab with low-dose reteplase for acute MI in 2 phases. Two heparin doses were also explored. Phase A patients were randomized 4:1 to receive an abciximab bolus with infusion alone (n = 63)…